Filing Analysis
Xilio Therapeutics, Inc. announced its financial results for the fiscal quarter ended June 30, 2026. The filing serves as a formal announcement of quarterly earnings and business highlights.
📋 Key Facts
- Report date: August 12, 2026
- Reporting period: Quarter ended June 30, 2026
- The company is an emerging growth company as defined by the SEC.
- Financial results were released via press release (Exhibit 99.1).
Xilio Therapeutics reported the results of its 2026 Annual Meeting of Stockholders held on June 10, 2026. The filing details the election of Class II directors, the ratification of Ernst & Young LLP as auditors, and the approval of an amended stock incentive plan.
📋 Key Facts
- Stockholders elected Akintunde Bello, Daniel Curran, Robert Ross, and Yuan Xu as Class II directors for three-year terms expiring in 2029.
- Dr. Daniel Curran resigned as a Class II director and was immediately re-appointed as a Class III director to rebalance the board classes.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Stockholders approved the Amended and Restated 2021 Stock Incentive Plan, specifically regarding the calculation of the annual evergreen increase to include shares underlying prefunded warrants.
Xilio Therapeutics announced its financial results for the first quarter ended March 31, 2026, and provided general business highlights. The information was disclosed via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The filing reports financial results for the fiscal quarter ended March 31, 2026.
- The announcement was made on May 12, 2026.
- The company furnished the results under Item 2.02 (Results of Operations and Financial Condition).
- The full press release is included as Exhibit 99.1.
Xilio Therapeutics announced a transition in its Board of Directors, appointing Dr. Cheryl R. Blanchard to succeed Christina Rossi, who resigned effective April 15, 2026. Dr. Blanchard will take on key leadership roles as Chair of the Compensation Committee and a member of the Audit Committee.
📋 Key Facts
- Dr. Cheryl R. Blanchard elected as a Class III director with a term expiring at the 2027 annual meeting.
- Christina Rossi resigned from the Board and all committees on April 15, 2026; the resignation was not due to any disagreement.
- Dr. Blanchard was appointed Chair of the Compensation Committee and a member of the Audit Committee.
- Dr. Blanchard's compensation includes an annual cash fee of $40,000 for Board service, $12,000 for Compensation Committee Chair, and $7,500 for Audit Committee membership.
- Equity compensation includes an initial grant of 10,000 stock options vesting over three years and eligibility for 5,000 annual stock options.
Xilio Therapeutics announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The filing serves to furnish the earnings press release and provide business highlights to investors.
📋 Key Facts
- Announced financial results for Q4 and full year 2025 on March 23, 2026.
- Information was furnished under Item 2.02 Results of Operations and Financial Condition.
- Included Exhibit 99.1, a press release detailing financial performance and business highlights.
Xilio Therapeutics announced a 1-for-14 reverse stock split effective March 13, 2026, primarily to regain compliance with the Nasdaq Capital Market's minimum bid price requirement. Post-split trading is scheduled to begin on March 16, 2026, under the existing ticker XLO.
🚩 Red Flags
- Reverse stock split (1-for-14 ratio).
- Non-compliance with Nasdaq minimum bid price requirement.
📋 Key Facts
- Reverse stock split ratio of 1-for-14.
- Effective time is 5:00 p.m. Eastern Time on March 13, 2026.
- Post-split trading begins at market open on March 16, 2026.
- The split is intended to address Nasdaq's minimum bid price requirement.
- No fractional shares will be issued; stockholders will receive cash in lieu of fractional shares.
- The number of authorized shares and par value ($0.0001) remain unchanged.
Xilio Therapeutics, Inc. updated its corporate investor presentation on March 9, 2026, to provide business updates to the investment community. The presentation is furnished as an exhibit to the filing in compliance with Regulation FD.
📋 Key Facts
- Updated corporate investor presentation released on March 9, 2026
- Presentation made available on the company's investor relations website
- Filed under Item 7.01 Regulation FD Disclosure
- Exhibit 99.1 contains the slide deck dated March 9, 2026
Xilio Therapeutics stockholders approved a reverse stock split at a ratio ranging from 1-for-2 to 1-for-30 during a special meeting on February 23, 2026. The board of directors has been granted the authority to determine the final ratio and the timing of the implementation.
🚩 Red Flags
- Reverse stock split approval (typically used to address share price deficiencies or maintain exchange listing requirements).
- Potential for significant dilution or loss of liquidity following a 1-for-30 consolidation.
📋 Key Facts
- Stockholders approved an amendment to the restated certificate of incorporation to effect a reverse stock split.
- The approved ratio range is between 1-for-2 and 1-for-30.
- The board of directors has sole discretion to determine the exact ratio and timing without further stockholder approval.
- Proposal 1 (Reverse Split) passed with 55,438,144 votes for and 1,521,271 against.
- An adjournment proposal was also approved, though not needed as Proposal 1 passed.
Xilio Therapeutics entered into an underwriting agreement to conduct a pre-funded warrant offering. The company expects to receive approximately $37.1 million in net proceeds from the sale of up to 74,780,300 warrants.
🚩 Red Flags
- Significant potential dilution: The offering involves up to ~74.8 million warrants at a very low exercise price ($0.0001), which will result in massive share count expansion upon exercise.
- Pre-funded warrant structure: Often used when companies cannot meet standard pricing requirements or are seeking rapid capital, typically signaling urgent cash needs.
📋 Key Facts
- Offering type: Underwritten offering of pre-funded warrants.
- Warrant quantity: Up to 74,780,300 warrant shares.
- Price per warrant: $0.5349.
- Exercise price: $0.0001 per share (immediately exercisable).
- Estimated net proceeds: Approximately $37.1 million.
- Underwriter: Leerink Partners LLC.
- Expected closing date: On or about February 13, 2026.
Xilio Therapeutics announced a leadership change in its Board of Directors and provided preliminary cash position estimates for the end of fiscal year 2025. Sara M. Bonstein has been appointed as Chair, succeeding Paul Clancy, who is retiring from the Board.
🚩 Red Flags
- Cash position is based on preliminary, unaudited information and management estimates only.
📋 Key Facts
- Estimated cash and cash equivalents: approximately $137.5 million as of December 31, 2025.
- Sara M. Bonstein appointed as Chair of the Board.
- Paul Clancy retired from the Board effective January 6, 2026; retirement was not due to any disagreement with management or the Company.
Xilio Therapeutics reports the expiration of Series B warrants and provides an update on its cash runway. The company successfully raised $35.8 million from Series B warrant exercises but faces upcoming Series C warrant expirations in late 2026.
🚩 Red Flags
- Significant dilution potential from the upcoming Series C warrant exercise window (June–Dec 2026).
- Heavy reliance on warrant exercises for liquidity/cash runway extension.
📋 Key Facts
- Series B warrants (66,676,000 issued) expired on December 31, 2025.
- 48,207,815 Series B warrants were exercised for $35.8 million in gross proceeds.
- Exercise resulted in 8,202,815 shares of common stock and 40,005,000 prefunded warrants.
- As of January 2, 2026, there are 67,540,930 shares of common stock outstanding.
- Series C warrants (48,207,815 remaining) are exercisable between June 1, 2026 and December 2, 2026 at $0.75 per warrant.
- Potential gross proceeds from Series C exercise: up to $36.2 million.
- Cash runway is expected to extend into the second quarter of 2027.
Xilio Therapeutics held a special meeting on November 21, 2025, where stockholders approved the adoption of the 2025 Stock Incentive Plan and a one-time repricing of certain executive stock options. The repricing reduced the exercise price for options held by the CEO, CFO/COO, and CMO from significantly higher levels to $1.50 per share.
🚩 Red Flags
- One-time repricing of executive stock options is often viewed as dilutive and potentially problematic for minority shareholders.
- Significant gap between previous strike prices ($4.10-$5.76) and the new price ($1.50) suggests a substantial decline in company valuation since option grants were made.
📋 Key Facts
- Stockholders approved the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (Proposal 2).
- Stockholders approved a one-time repricing of certain outstanding employee stock options (Proposal 1) with 31,600,793 votes in favor.
- The exercise price for the repriced options was reduced to $1.50 per share.
- CEO René Russo's option strike price was reduced from an average of $5.76 to $1.50.
- CFO/COO Christopher Frankenfield's option strike price was reduced from $4.67 to $1.50.
- CMO Katarina Luptakova's option strike price was reduced from $4.10 to $1.50.
- A 12-month 'clawback' provision exists: if exercised within a year, the original higher exercise price must be paid (unless due to death, disability, or change in control).
Xilio Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2025. The filing serves as a formal announcement of quarterly earnings and business highlights.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2025
- Announcement date: November 13, 2025
- The report includes financial results and other business highlights via Exhibit 99.1
- Company is an emerging growth company
Xilio Therapeutics issued two press releases containing clinical and preclinical data updates presented at the SITC 40th Annual Meeting. The data includes Phase 2 results for vilastobart, Phase 1 data for efarindodekin alfa, and preclinical platform updates.
📋 Key Facts
- Announced new data on high plasma tumor mutational burden from a Phase 2 clinical trial (vilastobart + atezolizumab) in metastatic colorectal cancer.
- Released updated portfolio data including preclinical data for the masked T cell engager platform.
- Provided updated Phase 1 data for efarindodekin alfa.
- Presented Phase 2 data related to circulating tumor DNA for vilastobart.
- All data was presented at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting on November 7, 2025.
Xilio Therapeutics is being transferred from the Nasdaq Global Select Market to the Nasdaq Capital Market effective October 6, 2025. This move follows a failure to maintain the $1.00 minimum bid price requirement.
🚩 Red Flags
- Delisting/Transfer of listing from a premium tier (Global Select) to a lower tier (Capital Market).
- Failure to maintain the minimum bid price requirement ($1.00 rule).
- Ongoing compliance risk regarding Nasdaq Listing Rule 5450(a)(1).
📋 Key Facts
- Nasdaq approved transfer of listing from The Nasdaq Global Select Market to The Nasdaq Capital Market.
- Transfer becomes effective at the opening of business on October 6, 2025.
- The company failed to maintain the $1.00 minimum bid price required under Nasdaq Listing Rule 5450(a)(1).
- Nasdaq has granted a 180-day grace period until March 30, 2026, to regain compliance.
- To regain compliance during the grace period, stock must close at $1.00 or more for at least 10 consecutive business days.
Xilio Therapeutics announced the initiation of Phase 2 dosing for its drug candidate efarindodekin alfa (XTX301) and the achievement of a $17.5 million development milestone from Gilead Sciences, Inc. The company also updated its cash runway guidance to extend into Q1 2027.
🚩 Red Flags
- Clinical trial execution risk associated with moving from Phase 1/2 to Phase 2 dosing.
📋 Key Facts
- Initiation of patient dosing in Phase 2 clinical trial for efarindodekin alfa (XTX301) as a monotherapy.
- Achievement of a $17.5 million development milestone under the license agreement with Gilead Sciences, Inc.
- The $17.5 million milestone payment is expected to be received by Q4 2025.
- As of June 30, 2025, cash and cash equivalents stood at $121.6 million.
- Updated guidance anticipates cash runway extending into the first quarter of 2027.
Xilio Therapeutics received a deficiency notice from Nasdaq for failing to maintain the minimum stockholders' equity requirement of $10.0 million, reporting only $7,069,000 as of June 30, 2025. This follows a previous deficiency regarding the minimum bid price requirement.
🚩 Red Flags
- Delisting notice regarding stockholders' equity deficiency.
- Existing non-compliance with Nasdaq's minimum bid price requirement.
- Multiple delisting/deficiency issues (Equity and Bid Price) occurring simultaneously.
- Imminent expiration of compliance periods for existing deficiencies.
📋 Key Facts
- Received Nasdaq deficiency letter on August 22, 2025, for violation of Nasdaq Listing Rule 5450(b)(1)(A).
- Stockholders' equity reported as $7,069,000 in the Q2 2025 Form 10-Q.
- The company has until October 6, 2025, to submit a plan to regain compliance with the equity requirement.
- The company is already out of compliance with the $1.00 minimum bid price requirement (Minimum Bid Requirement).
- The grace period for the Minimum Bid Requirement expires on October 1, 2025.
Xilio Therapeutics, Inc. announced its financial results for the second quarter ended June 30, 2025. The filing serves as a formal announcement of quarterly earnings and business highlights.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2025
- Announcement date: August 14, 2025
- The company is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.
- Financial results were released via press release (Exhibit 99.1).
Xilio Therapeutics, Inc. held its 2025 annual meeting of stockholders on June 10, 2025. The company successfully elected three Class I directors and obtained shareholder approval for significant amendments to its Certificate of Incorporation.
🚩 Red Flags
- Significant increase in authorized shares (from 200M to 600M) can lead to future dilution if used for equity financing.
📋 Key Facts
- Elected René Russo, Pharm.D., Sara M. Bonstein, and James Shannon, M.D. as Class I directors for three-year terms expiring in 2028.
- Approved a Share Increase Amendment to increase authorized common stock from 200,000,000 to 600,000,000 shares.
- Approved an Officer Exculpation Amendment to reflect Delaware law provisions.
- Ratified the selection of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2025.
Xilio Therapeutics, Inc. announced the election of Akintunde Bello, Ph.D., to its Board of Directors and his appointment to the Nominating and Corporate Governance Committee, effective June 10, 2025.
📋 Key Facts
- Effective date: June 10, 2025
- New Director: Akintunde Bello, Ph.D., elected as a Class II director
- Board expansion: Board size increased to ten directors
- Committee Appointment: Dr. Bello appointed to the Nominating and Corporate Governance Committee
- Term: Term expires at the 2026 annual meeting of stockholders or until successor is qualified
Xilio Therapeutics entered into an underwriting agreement for a significant public offering of pre-funded warrants and three series of common stock warrants (Series A, B, and C). The offering is expected to raise approximately $46.6 million in net proceeds.
🚩 Red Flags
- Significant potential dilution: The offering involves over 266 million total shares via various warrant series.
- Complex warrant structures (Series A, B, and C) with varying expiration dates and reset provisions.
- Price floor/Minimum purchase price constraints: Future equity issuances are restricted to a minimum of $1.50 per share (or $1.00 if certain conditions met), which may limit the company's ability to raise capital at higher valuations without holder approval.
📋 Key Facts
- Underwriting agreement signed with Leerink Partners LLC on June 2, 2025.
- Offering includes pre-funded warrants for 66,676,000 shares and Series A, B, and C warrants for 66,676,000 shares each.
- Combined offering price per unit is $0.7499.
- Estimated net proceeds from the offering are approximately $46.6 million.
- Potential additional gross proceeds of ~$100 million if Series B and C warrants are exercised in cash at their exercise price.
- Warrants include a 'non-dilutive capital' offset provision where certain milestone payments or equity issuances above $1.50/share can trigger the cancellation of warrants on a dollar-for-dollar basis.
Xilio Therapeutics issued an 8-K to provide updated clinical trial data from its Phase 2 study of vilastobart in combination with atezolizumab. The company also updated its corporate investor presentation on its website.
📋 Key Facts
- Updated Phase 2 clinical trial data for vilastobart + atezolizumab was presented at the 2025 ASCO Annual Meeting.
- The trial focuses on patients with metastatic microsatellite stable colorectal cancer.
- Company updated its corporate investor presentation (Exhibit 99.1).
- Press release regarding clinical data issued on May 31, 2025 (Exhibit 99.2).
Xilio Therapeutics, Inc. announced its financial results for the fiscal quarter ended March 31, 2025. The filing serves as a formal announcement of quarterly earnings and business highlights.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2025
- Announcement date: May 8, 2025
- The company is classified as an 'emerging growth company' under SEC rules.
Xilio Therapeutics received a deficiency notice from Nasdaq because its common stock closed below the $1.00 minimum bid price for 30 consecutive business days. The company has an initial 180-day period to regain compliance, expiring October 1, 2025.
🚩 Red Flags
- Delisting notice from Nasdaq
- Stock price has been below $1.00 for 30 consecutive business days
- Risk of delisting if minimum bid requirement is not met by October 2025
📋 Key Facts
- Received deficiency notice from Nasdaq on April 4, 2025.
- Violation of Nasdaq Listing Rule 5450(a)(1) regarding the $1.00 minimum bid requirement.
- Initial compliance period expires October 1, 2025 (180 calendar days).
- To regain compliance, stock must close at or above $1.00 for at least 10 consecutive business days.
- Potential for a second 180-day compliance period if the company transfers to Nasdaq Capital Market.
Xilio Therapeutics, Inc. has entered into an 'at-the-market' (ATM) sales agreement with Leerink Partners LLC to facilitate the potential sale of up to $50 million in common stock.
🚩 Red Flags
- Potential for significant shareholder dilution due to the $50 million ATM offering capacity.
📋 Key Facts
- Entered into a Sales Agreement with Leerink Partners LLC on March 11, 2025.
- The agreement allows for the sale of up to $50.0 million of common stock via an 'at-the-market' offering.
- Agent compensation is set at 3.0% of gross proceeds.
- Sales will be conducted through Nasdaq Global Select Market or directly via the Agent.
- The offering is based on a previously effective Form S-3 Registration Statement (File No. 333-268264).
Xilio Therapeutics announced its financial results for the quarter and fiscal year ended December 31, 2024. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Reporting period: Quarter and Year ended December 31, 2024.
- Announcement date: March 11, 2025.
- The filing includes Exhibit 99.1 containing the full text of the press release regarding financial results and business highlights.
Xilio Therapeutics entered into a major collaboration and license agreement with AbbVie, involving up to four programs leveraging Xilio's proprietary technology. The deal includes significant upfront cash/equity and substantial contingent milestone payments totaling up to $2.1 billion.
🚩 Red Flags
- Exclusivity clauses restrict Xilio from working with other partners for the specific targets/backups involved in the AbbVie programs.
📋 Key Facts
- Entered into a collaboration, license, and option agreement with AbbVie Group Holdings Limited on February 10, 2025.
- Agreement covers one exclusive Collaboration Program (masked antibody-based immunotherapy) and up to three Option Programs (masked T cell engagers).
- Total upfront consideration of $52.0 million ($42.0M cash + $10.0M equity at $2.30/share).
- Potential contingent payments totaling up to $2.1 billion, including $305M in fees and $1.8B in milestones.
- Xilio receives tiered royalties: high single digits for Option Programs and mid-single digits for the Collaboration Program.
- AbbVie completed a private placement of 4,347,826 shares at $2.30 per share on February 11, 2025.
- Company anticipates cash runway extending into Q1 2026 based on current plans and new proceeds.
Xilio Therapeutics announced the release of initial data from its Phase 2 clinical trial for vilastobart (XTX101) in combination with atezolizumab. The company also updated its corporate investor presentation.
🚩 Red Flags
- Clinical stage biotech risk: Results are preliminary and subject to radiology confirmation.
📋 Key Facts
- Announced initial data from ongoing Phase 2 clinical trial evaluating vilastobart (XTX101) + atezolizumab for advanced solid tumors.
- Data to be presented at the ASCO 2025 Gastrointestinal Cancer Symposium via poster presentation.
- Updated corporate investor presentation was released on January 21, 2025.
- The company maintains clinical trial collaborations with Roche and a license agreement with Gilead.
Xilio Therapeutics has completed its $25 million equity financing agreement with Gilead Sciences, Inc. via a final tranche of common stock and prefunded warrants. The company also provided updated financial guidance, stating current cash is sufficient into Q3 2025.
🚩 Red Flags
- Significant dilution through the issuance of prefunded warrants that can be exercised at a nominal price ($0.0001).
- Heavy reliance on a single strategic partner (Gilead) for capital infusions.
- Cash runway is limited, extending only into Q3 2025.
📋 Key Facts
- Completed the final installment of a Stock Purchase Agreement with Gilead Sciences, Inc.
- Issued 1,759,978 shares at $1.04 per share and prefunded warrants for up to 6,092,816 shares at $1.0399 per share on Dec 18, 2024.
- Received approximately $8.2 million in aggregate gross proceeds from the final tranche.
- Total aggregate investment from Gilead under the agreement has reached the maximum of $25.0 million.
- Prefunded warrants are exercisable at $0.0001 per share, subject to beneficial ownership limits (19.9%).
- Company anticipates existing cash and equivalents will fund operations into Q3 2025.
Xilio Therapeutics announced its financial results for the quarter ended September 30, 2024, and released initial Phase 1C clinical data for vilastobart (XTX101) in combination with atezolizumab. The company also updated its corporate investor presentation.
🚩 Red Flags
- Standard forward-looking statement risk disclosures regarding clinical trial outcomes and cash runway.
📋 Key Facts
- Reported financial results for the quarter ended September 30, 2024 (Item 2.02).
- Released initial data from Phase 1C clinical trial of vilastobart (XTX101) + atezolizumab in advanced solid tumors.
- Phase 1C data to be presented at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting.
- Updated corporate investor presentation released via website.
Xilio Therapeutics received a deficiency notice from Nasdaq because its common stock closed below the $1.00 minimum bid price for 30 consecutive business days. The company has an initial 180-day period to regain compliance, expiring March 10, 2025.
🚩 Red Flags
- Delisting notice (Nasdaq non-compliance)
- Stock price has been below $1.00 for at least 30 consecutive business days
- Risk of delisting from the Nasdaq Global Select Market
📋 Key Facts
- Received deficiency notice from Nasdaq on September 10, 2024.
- Violation of Nasdaq Listing Rule 5450(a)(1) regarding the $1.00 minimum bid requirement.
- Initial compliance period expires March 10, 2025 (180 days).
- To regain compliance, stock must close at or above $1.00 for at least 10 consecutive business days.
- Potential for a second 180-day compliance period if the company transfers to the Nasdaq Capital Market.
Xilio Therapeutics, Inc. announced its financial results for the second quarter ended June 30, 2024, and provided various business updates via a press release.
📋 Key Facts
- Report date: August 8, 2024
- Reporting period: Quarter ended June 30, 2024
- The filing includes the announcement of financial results and other business highlights.
Xilio Therapeutics, Inc. held its 2024 annual meeting of stockholders on June 13, 2024. The filing reports the election of two Class III directors and the ratification of Ernst & Young LLP as the independent auditor.
📋 Key Facts
- Annual meeting of stockholders held on June 13, 2024.
- Paul J. Clancy elected to Class III director (term expiring 2027).
- Christina Rossi elected to Class III director (term expiring 2027).
- Ernst & Young LLP ratified as independent registered public accounting firm for fiscal year ending Dec 31, 2024.
Xilio Therapeutics, Inc. announced the election of two new directors to its Board of Directors: James Shannon, M.D., and Aoife Brennan, M.D. The board size was increased from seven to nine members.
📋 Key Facts
- Effective June 13, 2024, the Board of Directors increased in size to nine directors.
- James Shannon, M.D., elected as a Class I director; term expires at 2025 annual meeting.
- Aoife Brennan, M.D., elected as a Class III director; term expires at 2027 annual meeting.
- Dr. Shannon appointed to the Nominating and Corporate Governance Committee.
- Dr. Brennan appointed to the Audit Committee.
Xilio Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2024. The filing serves as a formal announcement of quarterly earnings and business highlights.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2024
- Announcement date: May 14, 2024
- The company is an emerging growth company as defined by the SEC.
Xilio Therapeutics, Inc. announced its financial results for the fiscal quarter and year ended December 31, 2023. The filing serves as a formal announcement of quarterly earnings and business highlights.
📋 Key Facts
- Reporting period: Quarter and Year ended December 31, 2023.
- Announcement date: April 1, 2024.
- The company is classified as an 'emerging growth company'.
- Financial results were released via press release (Exhibit 99.1).
Xilio Therapeutics completed a private placement of 6,860,223 shares to Gilead Sciences, Inc. at $1.97 per share, totaling approximately $13.5 million. This follows an exclusive license agreement between Xilio's subsidiary and Gilead.
🚩 Red Flags
- Significant dilution: The issuance of new shares increased the total outstanding common stock by approximately 24.9%.
📋 Key Facts
- Private placement closed on March 28, 2024.
- Total aggregate purchase price of approximately $13.5 million.
- Issuance of 6,860,223 shares at a price of $1.97 per share.
- Common stock outstanding increased from 27,613,263 to 34,473,486 shares (a ~25% increase in share count).
- The transaction is linked to an exclusive license agreement with Gilead Sciences, Inc.
Xilio Therapeutics entered into a major exclusive license agreement with Gilead Sciences for its clinical-stage product candidate XTX301, involving significant upfront payments and milestone potential. The company also executed multiple private placements to raise capital via both strategic (Gilead) and non-strategic investors.
🚩 Red Flags
- Significant dilution: The company is issuing a large number of shares and prefunded warrants at prices ($0.64) significantly lower than the Gilead placement price ($1.97).
- Heavy reliance on contingent milestones for long-term value realization.
- The use of 'prefunded warrants' often indicates difficulty in raising capital through standard equity issuance.
📋 Key Facts
- Exclusive license agreement with Gilead Sciences for XTX301 (tumor-activated IL-12).
- Upfront payments of ~$43.5 million ($30M cash, $13.5M in common stock at $1.97/share).
- Potential contingent payments up to $604 million including a $75M transition fee and royalties.
- Gilead has the option to purchase up to ~$11.5 million in additional shares through March 2025.
- Securities Purchase Agreement with other investors for ~1.95M shares at $0.64/share and prefunded warrants at $0.6399.
- Estimated cash balance of approximately $44.7 million as of Dec 31, 2023.
Xilio Therapeutics received a deficiency notice from Nasdaq because its common stock closed below the $1.00 minimum bid price for 30 consecutive business days. The company has an initial 180-day period to regain compliance, expiring July 17, 2024.
🚩 Red Flags
- Delisting notice (Nasdaq non-compliance)
- Stock price performance below the $1.00 threshold
- Risk of delisting if compliance is not achieved within the 180-day window or subsequent extension period
📋 Key Facts
- Received deficiency notice from Nasdaq Listing Qualifications Department on January 19, 2024.
- Violation of Nasdaq Listing Rule 5450(a)(1) due to stock closing below $1.00 for 30 consecutive business days.
- Initial compliance period expires July 17, 2024.
- To regain compliance, the stock must close at or above $1.00 for at least 10 consecutive business days during the 180-day window.
- Potential for a second 180-day compliance period via transfer to Nasdaq Capital Market if initial requirements are not met.
Xilio Therapeutics announced annual equity awards granted to its CEO, René Russo, and SVP of Finance, Kevin Brennan, effective January 1, 2024.
📋 Key Facts
- CEO René Russo received an award of 177,000 restricted stock units (RSUs).
- SVP, Finance and Accounting Kevin Brennan received an award of 20,000 RSUs.
- RSUs vest in four equal annual installments starting January 1, 2025.
- Vesting is subject to continued service with the Company.